Pfizer discontinues Phase IIb of S. aureus vaccine

Pfizer Inc. (NYSE:PFE) discontinued the Phase IIb STRIVE trial of PF-06290510 to prevent postoperative invasive Staphylococcus aureus infections in patients

Read the full 203 word article

User Sign In